$SENS Breaks Out After Putting In Multiple Bottom

19 Feb 2020

SENS is finally breaking to the upside after putting in multiple bottoms at the $.80 to $.90 level. Yesterday, SENS put out news that we believe will continue to push the stock higher.

As always, trade with caution and use protective stops.

Good luck to all!

--Cigna coverage decision adds more than 17 million covered lives for Eversense CGM--

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Cigna is now providing coverage for the Eversense® CGM System, effective February 15, 2020. This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement.

Cigna Corporation is a global health service company dedicated to improving the health, well-being, and peace of mind of those who they serve. Cigna has more than 17 million medical customers and offers a Medicare Advantage plan in 17 states and Washington DC. This most recent coverage decision – in addition to Aetna (AET), Humana, HCSC Blue Cross Blue Shield and other health insurance providers – adds to the growing list of payers enabling their members to benefit clinically from the long-term Eversense CGM System.

“Cigna prides itself on providing choice and access to quality care through connected, personalized solutions that allow their members to harness actionable insights to drive better healthcare results. Now Cigna members will have the choice to use the only long-term implantable CGM system available to help them better manage their diabetes,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “Eversense provides actionable glucose data for users – not only where they are right now, but the direction they are headed. With superior accuracy, longest sensor life, on-body vibratory alerts and remote monitoring capability, users can proactively manage their glucose levels by treating their diabetes before they get to dangerously high or low levels. This information in the hands of the users allows them to manage their diabetes and experience healthier outcomes through personalized information and technology.”

The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor. Eversense users now have the freedom to make treatment decisions based on their Eversense readings. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.

Patients who are interested in getting started on Eversense can sign up at eversensediabetes.com/get-started-today. Physicians, nurse practitioners or physician assistants interested in offering the Eversense CGM System for their patients can contact 844-SENSE4U (844-736-7348).

About Eversense

The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see eversensediabetes.com/safety-info/.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.